HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SGN-30 monoclonal antibody

a chimeric anti-CD30 monoclonal antibody

Also Known As:

monoclonal antibody SGN-30

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        SGN-30 monoclonal antibody: 3
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        SGN-30 monoclonal antibody: 3
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        SGN-30 monoclonal antibody: 3

Experts

1.	Duvic, Madeleine: 1 article (10/2009)
2.	Kennedy, Dana A: 1 article (10/2009)
3.	Kim, Youn H: 1 article (10/2009)
4.	Korman, Neil J: 1 article (10/2009)
5.	Lorenz, Jennie: 1 article (10/2009)
6.	Pinter-Brown, Lauren: 1 article (10/2009)
7.	Reddy, Sunil A: 1 article (10/2009)
8.	Sievers, Eric L: 1 article (10/2009)
9.	Zic, John: 1 article (10/2009)
10.	Gerber, Hans-Peter: 1 article (12/2007)

Related Diseases

1.	Primary Cutaneous Anaplastic Large Cell Lymphoma 10/01/2009 - "An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell lymphoma (pc-ALCL), lymphomatoid papulosis (LyP), or transformed mycosis fungoides (T-MF). "
2.	Lymphomatoid Papulosis 10/01/2009 - "An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell lymphoma (pc-ALCL), lymphomatoid papulosis (LyP), or transformed mycosis fungoides (T-MF). "
3.	Mycosis Fungoides 10/01/2009 - "An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell lymphoma (pc-ALCL), lymphomatoid papulosis (LyP), or transformed mycosis fungoides (T-MF). "
4.	Neoplasms (Cancer) 12/15/2007 - "The anti-CD30 monoclonal antibody SGN-30 induces direct antitumor activity by promoting growth arrest and DNA fragmentation of CD30(+) tumor cells. "
5.	Hodgkin Disease (Hodgkin's Disease) 07/01/2002 - "The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease."